Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 14, 2007

Neuromed Banks $2M Milestone Payment from Merck & Co.

  • Neuromed Pharmaceuticals received a milestone payment of $2 million under its collaboration and license agreement with Merck & Co. In March 2006, the companies partnered to research, develop, and commercialize N-type calcium channel blockers for the treatment of pain and other disorders.

    "N-type calcium channels are an important target for pain,” states Christopher Gallen, president and CEO of Neuromed.  “Merck's commitment to this program gives it the highest chance to succeed in producing therapeutics for chronic pain and other underserved markets. "



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »